Tempus AI, Inc.

TEM · Nasdaq · ·

Compare

$79.41-1.4%Nov 11 close

Figures through September 30, 2026, from the 10-Q filed November 2, 2026

1W: +4.4%
1M: +16.4%

Tempus AI, Inc. (TEM) stock — is it a good business? — InspectStocks

Tempus AI, Inc.

TEM · Nasdaq · ·

Compare

$79.41-1.4%Nov 11 close

Figures through September 30, 2026, from the 10-Q filed November 2, 2026

1W: +4.4%
1M: +16.4%

Just reported

Q3 2026 results

From Tempus AI's results release of November 2, 2026; its quarterly report has since been filed.

Revenue
Actual
$411.5M
+23% y/y
+7.6% q/q
Guided
—
No guide given
EPS, GAAP
Actual
-$0.08
Guided
—
No guide given
Operating income, GAAP
Actual
-$56.9M
Guided
—
No guide given

Company outlook

Full year 2026

Revenue$1.6B – $1.605B+26% y/y Unchanged

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Tempus AI is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Health Information Services

Graded A or B and worth $2B or more: A first, then the largest.

All 41 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

How it makes money

Diagnostic testing75%
Data and applications25%

Shares of revenue are estimates for nine months ended September 30, 2026, not figures from a filing.

Competes with

What it sells6

Tempus|xT
A test of cancer tissue that looks for gene changes that may help doctors understand a cancer and choose treatment.
Tempus|xF
A blood test that looks for cancer-related genetic material circulating in the blood.
Tempus|xG
Tests that look for inherited gene changes linked to cancer risk and other inherited conditions.

Show 3 more

Insights
De-identified patient records and research tools that drug and biotechnology companies use to study diseases and develop medicines.
TIME Trial program
A service that helps doctors and drug companies find patients who may qualify for clinical trials.
Next
Software that checks patient information to help care teams spot missed tests or follow-up needs in cancer and heart care.

Who buys it4

Doctors, genetic counselors, and hospitals order tests for patients; insurers, government health programs, patients, or the ordering institution may pay.
Pharmaceutical and biotechnology companies buy de-identified patient data, research tools, and analysis services.
Drug companies pay for help identifying patients who may qualify for clinical trials.
Academic research institutions buy laboratory testing and related research services.

What it stands on, and what could break it

What the business leans on

1Its data business depends on continued access to patient records and permission to use and commercialize de-identified data.
2Clinical testing revenue depends in part on insurers and government health programs covering tests and paying enough to cover their cost.
3Laboratory testing relies on specialized instruments and materials from a limited number of suppliers, including some sole suppliers.
4The business depends on hospitals and other healthcare providers sharing data and using Tempus tests and software.

What could go wrong

1If Tempus loses access to patient data or cannot continue to use and license it, its research data and related services could be affected.
2Insurers or government health programs may decline to cover tests, reduce payment, or change reimbursement rules, affecting the amount Tempus collects for diagnostic work.
3Changes to rules for laboratory tests and AI-based medical tools could require additional approvals or oversight, delay products, or limit how Tempus can sell them.

Full financial statements →

About Tempus AI, Inc.

Tempus runs laboratory tests that examine a patient’s cancer or inherited health risks, then connects results with medical records and other patient information. It uses artificial intelligence (AI) to help doctors interpret results and identify possible treatments or clinical trials. Drug and biotechnology companies pay Tempus for de-identified patient data, research tools, and help finding patients for trials.

Head office: Chicago, Illinois
Founded: 2015
Listed on: Nasdaq
Financial year ends: December 31

Built from Tempus AI, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.

Just reported